Skip to main content

Advances in Cancer Medicine: Our Momentum of Discovery

 

Featured Content |Content Library

Forcing Cancer to Grow Up: Dana-Farber Scientists Reprogram Tumors to Behave Normally News

Forcing Cancer to Grow Up: Dana-Farber Scientists Reprogram Tumors to Behave Normally

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants News

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer News

Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer

Dana-Farber researchers present findings at 2025 San Antonio Breast Cancer Symposium News

Dana-Farber researchers present findings at 2025 San Antonio Breast Cancer Symposium

Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer News

Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer

Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer News

Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer

Education/CME

Receive Dana-Farber's
e-newsletter, Momentum,
to learn of advances in cancer research and care, current clinical trials, and upcoming CME programs.